Using the Systemic Inflammation Index (SII) as a Mid-Treatment Marker for Overall Survival among Patients Undergoing Chemo-Radiation Therapy for Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC): Secondary Analysis of PROCLAIM Trial
2020 ◽
Vol 108
(3)
◽
pp. S103-S104
2012 ◽
Vol 84
(3)
◽
pp. S154-S155
2010 ◽
Vol 78
(3)
◽
pp. S36
◽
Keyword(s):
2014 ◽
Vol 90
(1)
◽
pp. S669-S670
2016 ◽
Vol 96
(2)
◽
pp. E465-E466
Keyword(s):
2020 ◽
Vol 108
(3)
◽
pp. e95
Keyword(s):
2018 ◽
Vol 102
(3)
◽
pp. S92